Dr. Dorff on Current Agents for Patients With mCRPC

Tanya B. Dorff, MD
Published: Thursday, Nov 16, 2017



Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

There are several agents available to treat patients with mCRPC, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and docetaxel. However, patients treated with upfront intensification complicates the treatment process, says Dorff.

Novel agents, such as immunotherapy and PARP inhibitors, are being compared to these older agents in clinical trials, explains Dorff.


Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

There are several agents available to treat patients with mCRPC, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and docetaxel. However, patients treated with upfront intensification complicates the treatment process, says Dorff.

Novel agents, such as immunotherapy and PARP inhibitors, are being compared to these older agents in clinical trials, explains Dorff.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x